E1 ReplicatedPreliminaryPEM ✗RCTPeer-reviewedMachine draft
[The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson's disease].
Datieva, V K, Rosinskaia, A V, Levin, O S · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2013
Quick Summary
This study tested whether melatonin, a natural hormone that helps regulate sleep, could help Parkinson's disease patients who also experience chronic fatigue. Thirty patients took melatonin and showed a 21% improvement in fatigue, better sleep, less anxiety, and improved quality of life. The treatment did not significantly affect movement problems, thinking abilities, or depression.
Why It Matters
Chronic fatigue affects approximately 50% of Parkinson's disease patients and remains poorly treated. Since ME/CFS shares fatigue and circadian dysfunction with PD-related fatigue, understanding melatonin's efficacy in this population may inform novel therapeutic approaches for primary CFS. This work suggests circadian pathway interventions warrant further investigation in post-viral and idiopathic fatigue syndromes.
Observed Findings
- 21% statistically significant reduction in fatigue severity on the Parkinson Fatigue Scale (p<0.05)
- Improvement in sleep quality measured by the Parkinson's Disease Sleep Scale
- Statistically significant decrease in state anxiety on the Spielberger scale
- Improvement in quality of life on the PDQ-39 scale (p<0.05)
- No significant changes in motor symptoms, cognitive function, autonomic dysfunction, or depression levels
Inferred Conclusions
- Melatonin combined with optimized antiparkinsonian therapy can reduce fatigue severity in Parkinson's disease patients
- Melatonin may improve sleep disturbances and anxiety in this population
- Circadian and sleep pathway interventions may represent a viable treatment strategy for fatigue in neurodegenerative conditions
Remaining Questions
- How does melatonin's effect on PD-related fatigue compare to its potential efficacy in primary ME/CFS?
- What is the optimal melatonin dose and duration of treatment for maximum fatigue reduction?
- Can this open-label design be replicated as a randomized, placebo-controlled trial to establish true efficacy?
What This Study Does Not Prove
This study cannot establish that melatonin is effective for ME/CFS specifically, as the cohort consisted exclusively of Parkinson's disease patients with secondary fatigue. The lack of a randomized control arm or blinding means improvements could reflect placebo effect, natural disease course, or confounding effects from optimized antiparkinsonian medications. Findings cannot be generalized to primary CFS without dedicated controlled trials.
Tags
Symptom:Unrefreshing SleepFatigue
Method Flag:PEM Not DefinedSmall SampleMixed Cohort
Metadata
- PMID
- 23994935
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026